Bedrijfsoverzicht
Virax Biolabs Group Limited is a biotechnology entity dedicated to the distribution of diagnostic test kits designed for the prevention, detection, diagnosis, and risk management of viral diseases, specifically focusing on T cell in vitro diagnostics. The company operates within the broader healthcare sector, functioning specifically in the biotechnology industry, which typically involves high-risk, high-reward research and development environments. As of the latest available data, the company maintains a market capitalization of $772,779, generated from a trailing twelve-month revenue of $2,986, while employing a workforce of 19 individuals. These valuation and revenue figures indicate that Virax Biolabs Group Limited is a micro-cap enterprise with minimal operational scale, suggesting that its financial stability is heavily dependent on securing new contracts or successful product launches rather than established, recurring revenue streams. The disparity between the extremely low revenue and the market capitalization further highlights the speculative nature of its current market positioning, where the valuation is likely driven by potential future product pipeline value rather than current cash generation.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $2,986, yet this nominal income is overshadowed by a net income loss of $-5,643,591 and an EBITDA of $-5,556,497. The substantial gap between the minimal revenue of $2,986 and the massive net loss of $-5,643,591 reveals an extremely fragile cost structure where operating expenses far exceed any income generated from sales. Free cash flow stands at $-3,539,977, which indicates that the company is burning through cash reserves rapidly and possesses little to no financial flexibility to fund operations or investments without external financing. When analyzing profitability margins, the gross margin is recorded at 0.0%, the operating margin is a staggering -160788.3%, and the profit margin is also 0.0%, all figures suggesting that the company is unable to cover its direct costs or operational overheads relative to its sales volume. In terms of leverage, the company holds $3.44M in cash against a debt obligation of $537,993, resulting in a debt-to-equity ratio of 10.60, which suggests a highly leveraged balance sheet relative to its equity base despite the cash cushion. The current ratio is reported at 11.35, a figure that technically indicates strong short-term liquidity; however, given the gross margin of 0.0%, this liquidity is potentially illusory as the company cannot convert assets into profit. Return on equity is -83.8% and return on assets is -48.4%, metrics that reveal management is currently ineffective at generating returns on the capital invested by shareholders or creditors, likely due to the heavy losses incurred during the reporting period.
Waarderingsbeoordeling
The trailing P/E ratio is listed as N/A due to negative earnings, while the forward P/E is calculated at -0.43, implying that analysts or market data providers anticipate earnings that remain negative in the near term rather than a recovery to profitability. The price-to-book ratio stands at 0.13, indicating that the company's market valuation is significantly below its book value, a metric often associated with distressed assets or entities with intangible value not reflected on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 258.80 and an EV/EBITDA of 0.44 suggest that the market is pricing the stock based on revenue multiples despite the lack of profitability, which is common in early-stage biotechnology firms but carries significant risk if sales do not scale. The stock has traded within a 52-week range with a high of $1.20 and a low of $0.10; based on the provided data points, the current valuation sits at a level that reflects the extreme volatility typical of small-cap biotech stocks trading near their lower end of the historical range. The beta value of 1.60 indicates that the stock is expected to be 60% more volatile than the broader market, meaning price fluctuations will be amplified compared to large-cap indices. This high beta confirms that the asset class carries substantial systemic risk, where market downturns will likely result in disproportionately larger percentage losses for Virax Biolabs Group Limited compared to more stable sectors.
Growth & Income
Revenue growth year-over-year is recorded at -67.5%, while earnings growth is listed as N/A due to the lack of positive earnings to track, indicating that the company is contracting significantly rather than expanding its market footprint. The negative revenue growth implies that the company is losing market share or failing to sell sufficient quantities of its diagnostic kits to offset prior period performance, a situation where earnings cannot grow faster than revenue because the base revenue itself is shrinking. As a non-dividend payer, Virax Biolabs Group Limited reports a dividend yield of N/A and a payout ratio of 0.0%, meaning the company retains all its limited earnings—or in this case, losses—and reinvests them, or fails to, into growth initiatives rather than distributing income to shareholders. The overall growth and income profile is characterized by contraction in revenue and a complete absence of dividend income, reflecting the high-risk, high-potential but currently unprofitable nature of the biotechnology sector for this specific issuer.